Scientific Online Resource System

Scripta Scientifica Vox Studentium

Glucose variations and their impact on the treatment response in advanced colorectal cancer

Jonathan Souza Sarraf, Taynah Cascaes Puty, Gabriel Seabra Aguiar de Brito, Rebeca da Paixão Cleophas Cunha, Gércia Samilles Almeida Lira, Luis Eduardo Werneck de Carvalho, Luiz Fernando Affonso Fonseca, Fernando Adami


Introduction: Serum glucose is commonly associated with a bad clinical prognosis in many diseases, including colorectal cancer (CRC). However, the real impact of glucose variation (GV) on the treatment and prognosis of CRC patients is unknown. Due to the absence of information, this study aimed to correlate GV and treatment response in advanced CRC.

Materials and Methods: Thirty-eight CRC patients with stage III and IV disease were studied. The selected ones were those who have had two consecutive computed-tomography scans and more than one serum glucose (SG) test between the CT scans, which left 19 people of the original group.

Results: The mean age of the 19 analyzed subjects was 58.6 years SD=18.26; CI 95% 50.9 - 71.0. Most of the patients were men (59%), with Wilt-Type KRAS mutation (63.2%), without metastasis (71%) and at a clinical stage III (73.3%). No statistically significant value was found (p=0.126) between GV and treatment response in advanced CRC patients.

Conclusion: These findings cannot indicate a direct association between GV and treatment response in advanced CRC patient, but open space for evaluation of new methods of handling glucose variations in attempt to get a better understanding about how glucose may influence the CRC prognosis.


colorectal cancer, glucose variation, treatment response

Full Text


Lin JH, Zhang SM, Rexrode KM, Manson JE, Chan AT, Wu K, et al. Association between sex hormones and colorectal cancer risk in men and women. Clin Gastroenterol Hepatol. 2013;11(4):419-424.e1. doi: 10.1016/j.cgh.2012.11.012

Instituto Nacional do câncer José de Alencar (INCA), Estimativa 2016/2017, 2016. (Accessed 23 de Janeiro 2016).

Limburg PJ, Stolzenberg-Solomon RZ, Vierkant RA, Roberts K, Sellers TA, Taylor PR, et al. Insulin, glucose, insulin resistance, and incident colorectal cancer in male smokers. Clin Gastroenterol Hepatol. 2006;4(12):1514-21.

Sharma A, Ng H, Kumar A, Teli K, Randhawa J, Record J, et al. Colorectal cancer: Histopathologic differences in tumor characteristics between patients with and without diabetes. Clin Colorectal Cancer. 2014;13(1):54-61. doi: 10.1016/j.clcc.2013.10.002

Shen Z, Ye Y, Bin L, Yin M, Yang X, Jiang K, et al. Metabolic syndrome is an important factor for the evolution of prognosis of colorectal cancer: survival, recurrence, and liver metastasis. Am J Surg. 2010 Jul;200(1):59-63. doi: 10.1016/j.amjsurg.2009.05.005

Shin HY, Jung KJ, Linton JA, Jee SH. Association between fasting serum glucose levels and incidence of colorectal cancer in Korean men: the Korean Cancer Prevention Study-II. Metabolism. 2014 Oct;63(10):1250-6. doi: 10.1016/j.metabol.2014.07.006

Martinez-Outschoorn U, Sotgia F, Lisanti MP. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. Semin Oncol. 2014;41(2):195-216. doi: 10.1053/j.seminoncol.2014.03.002

Estevez-Garcia P, Rivera F, Molina-Pinelo S, Benavent M, Gómez J, Limón ML, et al. Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer. Oncotarget. 2015;6(8):6151-9.

Egi M, Bellomo R, Stachowski E, French CJ, Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology. 2006;105(2):244-52.

Lazzeri C, Valente S, Chiostri M, D'Alfonso MG, Gensini GF. Prognostic impact of early glucose variability in acute heart failure patients. Int J Cardiol. 2014;177(2):693-5. doi: 10.1016/j.ijcard.2014.09.150

Zhang XL, Lu JM, Shan GL, Yang ZJ, Yang WY. Association between glucose variability and adverse in-hospital outcomes for Chinese patients with acute coronary syndrome. Saudi Med J. 2010;31(10):1146-51.

Bragd J, Adamson U, Bäcklund LB, Lins PE, Moberg E, Oskarsson P. Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade? Diabetes Metab. 2008;34(6 Pt 1):612-6. doi: 10.1016/j.diabet.2008.04.005

Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002;11(4):385-91.

Taniguchi L, Higurashi T, Uchiyama T, Kondo Y, Uchida E, Uchiyama S, et al. Metabolic factors accelerate colorectal adenoma recurrence. BMC Gastroenterol. 2014;14:187. doi: 10.1186/1471-230X-14-187

Yang YX, Hennessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology. 2004;127(4):1044-50.

Dehal AN1, Newton CC, Jacobs EJ, Patel AV, Gapstur SM, Campbell PT. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012;30(1):53-9. doi: 10.1200/JCO.2011.38.0303

You J, Liu WY, Zhu GQ, Wang OC, Ma RM, Huang GQ, et al. Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer. Oncotarget. 2015;6(23):19880-90.

Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the `RASCAL II`study. Br J Cancer. 2001;85(5):692-6.

Andreyev HJ1, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter `RASCAL` study. J Natl Cancer Inst. 1998 May 6;90(9):675-84.

Bader T, Ismail A. Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: Propensity for lung metastasis. Alexandria J Med. 2014; 50(3):203-9. doi: 10.1016/j.ajme.2014.01.003

Bando H, Yoshino T, Yuki S, Shinozaki E, Nishina T, Kadowaki S, et al. Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan. Jpn J Clin Oncol. 2012;42(12):1146-51. doi: 10.1093/jjco/hys160

Calistri D, Rengucci C, Seymour I, Lattuneddu A, Polifemo AM, Monti F, et al. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression. J Cell Physiol. 2005;204(2):484-8.

Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, Galais MP, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer. 2007;96(8):1166-9

Gajate P, Sastre J, Bando I, Alonso T, Cillero L, Sanz J, et al. Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. Clin Colorectal Cancer. 2012;11(4):291-6. doi: 10.1016/j.clcc.2012.02.003

Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J J Clin Oncol. 2008;26(3):374-9. doi: 10.1200/JCO.2007.12.5906

Mellbin LG, Malmberg K, Rydén L, Wedel H, Vestberg D, Lind M. The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes: a report from the DIGAMI 2 trial. Eur Heart J. 2013 Feb;34(5):374-9. doi: 10.1093/eurheartj/ehs384

Pandey NR, Bian YY, Shou ST. Significance of blood pressure variability in patients with sepsis. World J Emerg Med. 2014;5(1):42-7. doi: 10.5847/wjem.j.1920-8642.2014.01.007

Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia. 2007;50(12):2553-61

Dias de Carvalho T, Marcelo Pastre C, Claudino Rossi R, de Abreu LC, Valenti VE, Marques Vanderlei LC. Ãndices geométricos de variabilidade da frequência cardíaca na doença pulmonar obstrutiva crônica. Rev Port Pneumol. 2011;17(6):260-5. doi: 10.1016/j.rppneu.2011.06.007



Font Size